Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,136,786 shares, an increase of 47.4% from the December 15th total of 4,164,492 shares. Approximately 17.2% of the shares of the company are short sold. Based on an average trading volume of 750,490 shares, the short-interest ratio is currently 8.2 days. Based on an average trading volume of 750,490 shares, the short-interest ratio is currently 8.2 days. Approximately 17.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DNTH shares. HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wedbush reaffirmed an “outperform” rating and set a $46.00 price target on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, Truist Financial raised their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $64.43.

Dianthus Therapeutics Stock Up 0.2%

Shares of DNTH traded up $0.10 during trading hours on Friday, hitting $44.10. The company had a trading volume of 638,611 shares, compared to its average volume of 757,049. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $46.59. The stock’s 50 day moving average price is $41.59 and its 200 day moving average price is $32.98. The firm has a market cap of $1.89 billion, a P/E ratio of -12.67 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. On average, research analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The disclosure for this sale is available in the SEC filing. Insiders sold 216,538 shares of company stock valued at $8,283,175 over the last ninety days. Corporate insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares during the period. AlphaQuest LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $94,000. Ensign Peak Advisors Inc purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $2,504,000. American Century Companies Inc. raised its position in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth approximately $503,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.